A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma

Cancer

Volumn 116, Issue 6, 2010, Pages 1526-1534

  Hersey, Peter ^a   Sosman, Jeffrey ^b   O'Day, Steven ^c   Richards, Jon ^d   Bedikian, Agop ^e   Gonzalez, Rene ^f   Sharfman, William ^g   Weber, Robert ^h   Logan, Theodore ⁱ   Buzoianu, Manuela ^j   Hammershaimb, Luz ^j   Kirkwood, John M ^k  

^a Newcastle Melanoma Unit   (Australia)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c Cancer Institute Medical Group   (United States)

^d Oncology Specialists   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h Saint Francis Memorial Hospital   (United States)

ⁱ INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^j MEDIMMUNE   (United States)

^k UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

more..

Author keywords

Alpha v beta 3; Clinical trials; Etaracizumab (Abegrin); Melanoma

Indexed keywords

ABEGRIN; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; DACARBAZINE; ETARACIZUMAB; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ACUTE HEART INFARCTION; ADULT; AGED; AIRWAY OBSTRUCTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHUS OBSTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELLULITIS; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE SEVERITY; DIVERTICULOSIS; DIZZINESS; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GUILLAIN BARRE SYNDROME; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMATURIA; HUMAN; HYDRONEPHROSIS; HYPERGLYCEMIA; HYPERHIDROSIS; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATASEMIA; HYPOTENSION; INSOMNIA; INTERMETHOD COMPARISON; LEUKOPENIA; LIQUORRHEA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MONOTHERAPY; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RESPIRATORY DISTRESS; SIDE EFFECT; SPINAL CORD COMPRESSION; SURVIVAL RATE; SURVIVAL TIME; SYNCOPE; THORAX PAIN; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT RESPONSE; UPPER GASTROINTESTINAL BLEEDING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTEGRIN ALPHAVBETA3; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS;

EID: 77949394260     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24821     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648.
3. Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: A pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. 2000;18:3782-3793.
4. Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: A meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res. 2001;11:75-81.
5. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: Thirty-year experience overview. J Exp Clin Cancer Res. 2000;19:21-34.
6. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745-2751.
7. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-166.
8. Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol. 1998;16:1743-1751.
9. Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study. J Clin Oncol. 2004;22:1118-1125.
10. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J Clin Oncol. 2006;24:4738-4745.
11. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105-2116.
12. Flaherty LE, Atkins M, Sosman J, et al. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: Results of 2 phase II cytokine working group trials. J Clin Oncol. 2001;19:3194-3202.
13. Danson S, Lorigan P, Arance A, et al. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol. 2003;21:2551-2557.
14. Agarwala SS, Glaspy J, O'Day SJ, et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol. 2002;20:125-133.
15. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J Clin Oncol. 2002;20:2045-2052.
16. Wu H, Beuerlein G, Nie Y, et al. Stepwise in vitro affinity maturation of vitaxin, an alphav beta3-specific humanized mAb. Proc Natl Acad Sci U S A. 1998;95:6037-6042.
17. Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol. 1993;5:864-868.
18. Horton MA. The alpha v beta 3 integrin "vitronectin receptor". Int J Biochem Cell Biol. 1997;29:721-725.
19. Eliceiri BP, Cheresh DA. The role of alphav integrins during angiogenesis. Mol Med. 1998;4:741-750.
20. Eliceiri BP, Cheresh DA. The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development. J Clin Invest. 1999;103:1227-1230.
21. Varner JA, Brooks PC, Cheresh DA. REVIEW: The integrin alpha V beta 3: Angiogenesis and apoptosis. Cell Adhes Commun. 1995;3:367-374.
22. Mitjans F, Meyer T, Fittschen C, et al. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer. 2000;87:716-723.
23. McNeel DG, Eickhoff J, Lee FT, et al. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res. 2005;11:7851-7860.
24. Moschos SJ, Sander CA, Wang W, et al. Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma. J Immunother. 2010. In press.
25. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
26. Creekmore SP, Longo DL, Urba WJ. Principles of the Clinical Evaluation of Biologic Agents. In: DeVita VTJ, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer. Philadelphia, Pa: JB Lippincott; 1991:67-86.
27. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. 2nd ed. New York: Springer; 2003.
28. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26:527-534.
29. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634.
30. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.
31. Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: A review of clinical trials. Cancer Chemother Pharmacol. 2008;61:535-548.
32. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
33. Avastin [package insert]. South San Francisco, CA; Genentech, Inc.; 2006.